Literature DB >> 29439311

Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma.

Xianguang Zhao1, Yang Chen2, Qiqi Mao1, Xiaoyun Jiang3, Weiru Jiang3, Jiajie Chen1, Weijia Xu1, Liang Zhong3, Xu Sun3.   

Abstract

In China, hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer and the leading cause of cancer death in men, followed by lung and stomach cancer. There was an urgent need to identify novel prognostic biomarkers for HCC. We explored the expression pattern of m6A related proteins in HCC tissues by using TCGA in this study. We found that the m6A 'reader' YTHDF1 was significantly upregulated in HCC and was positive correlated with pathology stage. Kaplan-Meier analysis showed that Lower YTHDF1 expression level was associated with better survival of HCC patients. Furthermore, we performed GO and KEGG pathway analysis of YTHDF1 co-expressed genes and found YTHDF1 played an important role in regulating HCC cell cycle progression and metabolism. We believed that this study will provide a potential new therapeutic and prognostic target for HCC.

Entities:  

Keywords:  HCC; YTHDF1; biomarker; m6A; prognostic

Mesh:

Substances:

Year:  2018        PMID: 29439311     DOI: 10.3233/CBM-170791

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  87 in total

1.  m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation.

Authors:  Jie Li; Lijun Zhu; Yanhong Shi; Jingnan Liu; Lin Lin; Xi Chen
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 2.  N6-methyladenine RNA modification and cancer.

Authors:  Jun Yang; Junwen Chen; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

3.  Expression patterns and prognostic value of m6A-related genes in colorectal cancer.

Authors:  Xin Liu; Liwen Liu; Zihui Dong; Jianhao Li; Yan Yu; Xiaolong Chen; Fang Ren; Guangying Cui; Ranran Sun
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 4.  Functions of RNA N6-methyladenosine modification in cancer progression.

Authors:  Bing Chen; Ya Li; Ruifeng Song; Chen Xue; Feng Xu
Journal:  Mol Biol Rep       Date:  2019-02-20       Impact factor: 2.316

Review 5.  Functions of RNA N6-methyladenosine modification in cancer progression.

Authors:  Bing Chen; Ya Li; Ruifeng Song; Chen Xue; Feng Xu
Journal:  Mol Biol Rep       Date:  2019-03-25       Impact factor: 2.316

Review 6.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

7.  Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma.

Authors:  Nobuhiko Nakagawa; Fuminori Sonohara; Katsuhito Tanaka; Yuki Sunagawa; Yoshikuni Inokawa; Hideki Takami; Masamichi Hayashi; Suguru Yamada; Mitsuro Kanda; Chie Tanaka; Goro Nakayama; Masahiko Koike; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 2.967

8.  YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.

Authors:  Jian Hu; Dongxu Qiu; Anze Yu; Jiao Hu; Hao Deng; Huihuang Li; Zhenglin Yi; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-05-06       Impact factor: 6.244

Review 9.  Role of m6A in osteoporosis, arthritis and osteosarcoma (Review).

Authors:  Yibo Hu; Xiaohui Zhao
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

10.  Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.

Authors:  Hongye Jiang; Gang Ning; Yensheng Wang; Weibiao Lv
Journal:  Dis Markers       Date:  2021-06-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.